journal
https://read.qxmd.com/read/36949725/sensory-irritation-to-methylparaben-is-caused-by-its-low-metabolism-in-the-skin
#1
JOURNAL ARTICLE
Rie Ninomiya, Takafumi Nishijima, Masahiro Aoshima, Hitoshi Sakaguchi, Yoshiki Tokura
Sensitive skin is a well- known skin condition showing sensory irritation to daily used products such as cosmetics or pharmaceuticals, possibly containing sensory irritants. Methylparaben (MP), widely used as a preservative, is a representative sensory irritant and hydrolyzed in the skin. We aimed to clarify the relationship between MP sensory irritation and MP hydrolysis. First, we investigated the percutaneous penetration and hydrolysis of MP by using an ex vivo pig skin system and confirmed that topically applied MP was immediately hydrolyzed to p-hydroxybenzoic acid (PHBA)...
March 22, 2023: Journal of Dermatology
https://read.qxmd.com/read/36949651/zoster-associated-pain-relief-on-the-left-trigeminal-nerve-v1-accompanied-by-improvement-of-the-syndrome-of-inappropriate-secretion-of-antidiuretic-hormone
#2
LETTER
Ai Yoshida, Shujiro Hayashi, Yuki Komatsuzaki, Ken Igawa
No abstract text is available yet for this article.
March 22, 2023: Journal of Dermatology
https://read.qxmd.com/read/36942530/paraneoplastic-secretion-of-antidiuretic-hormone-in-merkel-cell-carcinoma-a-case-report
#3
LETTER
Joan M Mercadé-Torras, Carla Samaniego, Amparo Sáez, Mireia Yebenes, Isabel Mazarico
No abstract text is available yet for this article.
March 21, 2023: Journal of Dermatology
https://read.qxmd.com/read/36938687/symptomatic-dermographism-induced-by-oral-minocycline-a%C3%A2-report-of-four-cases
#4
JOURNAL ARTICLE
Xianjie Yang, Minmin Kong, Huan Wang, Zhiqiang Song, Qiquan Chen
Symptomatic dermographism (SD) is the most common form of chronic inducible urticarias. The etiology of this disease has rarely been reported in the literature. Minocycline is widely used in the treatment of acne, rosacea, and other inflammatory skin diseases. Herein we report four cases of SD onset during minocycline administration. These were young women in their 20s to 30s who were taking minocycline orally for acne vulgaris or rosacea. They all experienced the onset of SD 2-3 weeks after taking the drug, and then the complete disappearance of SD 1 month after stopping the drug...
March 20, 2023: Journal of Dermatology
https://read.qxmd.com/read/36938674/four-year-drug-survival-of-apremilast-in-patients-with-psoriasis
#5
JOURNAL ARTICLE
Megumi Kishimoto, Mayumi Komine, Koji Kamiya, Junichi Sugai, Aya Kuwahara, Mamitaro Ohtsuki
This real-world study at a single academic center retrospectively examined the drug survival of apremilast for patients with psoriasis. Retrospective information was extracted from the medical records of patients with psoriasis treated with apremilast at the Department of Dermatology, Jichi Medical University Hospital, between March 1, 2017, and June 31, 2021. In total, 281 patients were included in this study. Of these patients, 22% had psoriatic arthritis and 57% had a history of prior systemic treatment, including biologics, before the initiation of apremilast...
March 20, 2023: Journal of Dermatology
https://read.qxmd.com/read/36938668/epidemiological-study-of-antifungal-resistant-dermatophytes-isolated-from-japanese-patients
#6
JOURNAL ARTICLE
Junichiro Hiruma, Hiromitsu Noguchi, Tatsuya Shimizu, Masataro Hiruma, Kazutoshi Harada, Rui Kano
An epidemiological study of antifungal drug-resistant dermatophytes was conducted as a follow-up to our 2020 survey. Dermatophytes were isolated in 2022 from the same dermatology clinics as in the previous study. In total, 288 Trichophyton interdigitale and Trichophyton rubrum clinical isolates were obtained from 288 human cases of dermatophytosis in Tokyo, Saitama, Shizuoka, and Kumamoto, Japan. Four strains were found to be resistant to terbinafine (TRF) and susceptible to itraconazole (ITZ), luliconazole (LCZ), and ravuconazole (RVZ), and three other strains were found to be resistant to ITZ and susceptible to TRF, LCZ, and RVZ...
March 20, 2023: Journal of Dermatology
https://read.qxmd.com/read/36938663/identification-of-skin-infiltrating-donor-lymphocytes-in-a-case-of-pre-engraftment-syndrome
#7
LETTER
Keiko Sakamoto, Ibuki Takatsuka, Tomonari Takemura, Takaaki Ono, Yuka Nagakura, Svetlana D Pack, Keisuke Nagao, Tetsuya Honda
No abstract text is available yet for this article.
March 20, 2023: Journal of Dermatology
https://read.qxmd.com/read/36938660/whole-exome-sequencing-of-secondary-tumors-arising-from-nevus-sebaceous-revealed-additional-genomic-alterations-besides-ras-mutations
#8
JOURNAL ARTICLE
Yoon-Seob Kim, Gyeong Sin Park, Yeun-Jun Chung, Ji Hyun Lee
Nevus sebaceous (NS) is a congenital hamartoma associated with an increased risk of secondary neoplasms in approximately 10%-20% of patients. However, additional genomic alterations underlying tumorigenesis in NS lesions have not been clarified. We performed whole-exome sequencing of archived tumor tissues (n = 8; six basal cell carcinomas and two trichoepitheliomas) and matched germline tissues (n = 7) with from seven patients with secondary tumors arising from NS. We also analyzed NS lesions without secondary tumors (n = 8)...
March 20, 2023: Journal of Dermatology
https://read.qxmd.com/read/36938658/epstein-barr-virus-dna-measurement-in-skin-tumor-lesions-might-be-a-sensitive-diagnostic-marker-of-recurrence-in-patients-with-nasal-type-extranodal-nk-t-cell-lymphoma-a-case-report
#9
LETTER
Naho Yokota, Makoto Kondo, Yoshiaki Matsushima, Koji Habe, Keiichi Yamanaka
No abstract text is available yet for this article.
March 20, 2023: Journal of Dermatology
https://read.qxmd.com/read/36938655/chinese-nontwin-sisters-suffer-from-poikiloderma-with-neutropenia-harboring-novel-compound-heterozygous-usb1-gene-mutations
#10
LETTER
Cong Yan, Tong Zhou, Songmei Geng
No abstract text is available yet for this article.
March 20, 2023: Journal of Dermatology
https://read.qxmd.com/read/36938650/treatment-for-taxane-resistant-cutaneous-angiosarcoma-a-multicenter-study-of-50-japanese-cases
#11
JOURNAL ARTICLE
Taku Fujimura, Takeo Maekawa, Hiroshi Kato, Takamichi Ito, Shigeto Matsushita, Koji Yoshino, Yasuhiro Fujisawa, Shoichiro Ishizuki, Kojiro Segawa, Jun Yamamoto, Akira Hashimoto, Yumi Kambayashi, Yoshihide Asano
Cutaneous angiosarcoma (CAS) is a rare and highly aggressive type of vascular tumor. Although chemoradiotherapy with taxanes is recognized as a first-line therapy for CAS, second-line therapy for CAS remains controversial. From the above findings, the efficacy and safety profiles of taxane-switch (change paclitaxel to docetaxel or vise), eribulin methylate, and pazopanib regimens in second-line chemotherapy were evaluated retrospectively in 50 Japanese taxane-resistant CAS patients. Although there was no significant difference in progression-free survival (P = 0...
March 20, 2023: Journal of Dermatology
https://read.qxmd.com/read/36938647/nevus-anemicus-with-immature-melanogenesis-and-droplets-of-melanocytes-in-a-patient-with-nevus-anemicus-nevus-flammeus-and-mixed-vascular-nevus
#12
LETTER
Mai Hamaguchi, Yushiro Ohara, Maki Nakajima, Tomoko Wakasa, Naoki Oiso
No abstract text is available yet for this article.
March 20, 2023: Journal of Dermatology
https://read.qxmd.com/read/36914982/dupilumab-associated-cutaneous-adverse-events-among-adult-patients-with-atopic-dermatitis-a-retrospective-study
#13
JOURNAL ARTICLE
Maddalena Napolitano, Gabriella Fabbrocini, Cataldo Patruno
Dupilumab, a monoclonal antibody inhibiting interleukin (IL) 4 and IL-13, is approved for the treatment of moderate to severe atopic dermatitis (AD) in children aged ≥6 years, adolescents, and adults. Both clinical trials and real-life data demonstrate its efficacy and safety. However, some cutaneous adverse events (cAEs) have been observed during real-world experiences. The authors' aim was to analyze the spectrum of cAEs in patients receiving dupilumab for the treatment of AD in a real-world setting...
March 13, 2023: Journal of Dermatology
https://read.qxmd.com/read/36914981/pyodermatitis-pyostomatitis-vegetans-affecting-peristomal-skin
#14
LETTER
Anna Ochi, Yasuhiro Mitsui, Kohei Ogawa, Shinji Nakamura, Kohei Morita, Kentaro Hamakawa, Toru Kurimoto, Hideo Asada
No abstract text is available yet for this article.
March 13, 2023: Journal of Dermatology
https://read.qxmd.com/read/36914976/a-case-of-acquired-idiopathic-generalized-anhidrosis-following-severe-acute-respiratory-syndrome-coronavirus-2-vaccination
#15
LETTER
Atsuyoshi Ginoza, Reiko Kageyama, Norihito Suzuki, Takatoshi Shimauchi, Toshiharu Fujiyama, Taisuke Ito, Tetsuya Honda
No abstract text is available yet for this article.
March 13, 2023: Journal of Dermatology
https://read.qxmd.com/read/36914975/indirect-immunofluorescence-for-bullous-pemphigoid-using-ex-vivo-confocal-laser-scanning-microscopy
#16
LETTER
Işın Sinem Bağcı, Ecem Zeliha Ergün, Pinar Avci, Rui Aoki, Sebastian Krammer, Gabriela Vladimirova, Miklós Sárdy, Thomas Ruzicka, Daniela Hartmann
No abstract text is available yet for this article.
March 13, 2023: Journal of Dermatology
https://read.qxmd.com/read/36890685/efficacy-and-safety-of-baricitinib-treatment-for-moderate-to-severe-atopic-dermatitis-in-real-world-practice-in-japan
#17
JOURNAL ARTICLE
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda
The authors evaluated the efficacy and safety of baricitinib, a Janus kinase 1/2 inhibitor, for atopic dermatitis (AD) in real-world practice. From August 2021 to September 2022, 36 patients aged ≥15 years with moderate to severe AD were treated with oral baricitinib 4 mg/day plus topical corticosteroids. Baricitinib improved clinical indexes; the percent reduction at weeks 4 and 12 was a median of 69.19% and 69.98% for the Eczema Area and Severity Index (EASI), 84.52% and 76.33% for the Atopic Dermatitis Control Tool, and 76...
March 8, 2023: Journal of Dermatology
https://read.qxmd.com/read/36890683/age-distribution-and-prevalence-in-different-age-groups-of-four-myositis-specific-autoantibodies-including-anti-ars-anti-mda5-anti-mi-2-and-anti-tif1%C3%AE-antibodies
#18
JOURNAL ARTICLE
Ikuko Ueda-Hayakawa, Kyoko Tonomura, Aya Maekawa, Emi Kaneda, Noriko Arase, Manabu Fujimoto
We accumulated the demographic information and analyzed the prevalence of myositis-specific antibodies (MSAs) in a large cohort across Japan as standard testing for MSAs becomes more widely available. This retrospective, observational, cohort study analyzed the records of individuals aged 0-99 years who are tested for serum MSAs at SRL Incorporation from January 2014 to April 2020 across Japan. An enzyme-linked immunosorbent assay testing was applied to determine the presence of anti-aminoacyl tRNA synthetase (anti-ARS), anti-Mi-2, anti-melanoma differentiation-associated gene 5 (anti-MDA5), or anti-transcriptional intermediary factor 1-γ (anti-TIF1γ) (Medical and Biological Laboratories)...
March 8, 2023: Journal of Dermatology
https://read.qxmd.com/read/36890675/final-analysis-of-a-post-marketing-surveillance-study-of-dabrafenib-and-trametinib-combination-therapy-in-japanese-patients-with-unresectable-malignant-melanoma-with-braf-v600-mutation
#19
JOURNAL ARTICLE
Tomoaki Kaizuka, Ryohei Kurihara, Miki Harumiya, Takayuki Kimura, Naoko Ushida
Targeted therapy with a combination of dabrafenib and trametinib has been developed and widely used for treatment of melanoma. However, data regarding its safety and efficacy in Japanese patients with malignant melanoma are limited. A post-marketing surveillance (PMS) study was conducted to investigate the safety and efficacy of combination therapy in a Japanese clinical setting with a surveillance period of June 2016 to March 2022; 326 patients with unresectable malignant melanoma with BRAF mutation were enrolled...
March 8, 2023: Journal of Dermatology
https://read.qxmd.com/read/36890674/case-of-type-1-segmental-darier-s-disease-with-a-novel-mosaic-mutation-in-the-atp2a2-gene
#20
JOURNAL ARTICLE
Keisuke Shimizu, Hideki Fujita, Daisuke Fujisawa, Koremasa Hayama, Satomi Aoki, Akiharu Kubo, Tadashi Terui
No abstract text is available yet for this article.
March 8, 2023: Journal of Dermatology
journal
journal
20148
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.